For Investors & Partners

Market Opportunity

The home-care market is valued at $390 billion, growing at a CAGR of 8%.

The U.S. sees 6 million CVAD lines inserted annually, with a CAGR of 2.4%.

Hospitals face additional fines of 1% of annual revenue for safety violations, driving demand for solutions that improve outcomes and reduce costs.

The annual cost of complications, including $2.3 billion due to line contamination, totals $6.5 billion, a burden hospitals bear due to a lack of insurance reimbursement.

Initially targeting oncology centers, where patients undergo frequent blood tests, the product leverages relevant reimbursement codes.

Problem & Solution

VenoBotic's product addresses these needs, aligning with value-based care trends and the shift toward home care.

Competitive Advantage

There is no existing device offering a fully autonomous solution for blood collection, flushing and disinfection from central catheters. Current approaches, including manual techniques, syringes, and mechanical devices, address the issue only partially, leaving a significant gap in the market for an automatic, comprehensive solution.

Intellectual Property (IP)

Patent application filed - April 2023 (WO2024209465A1).

Financing & Status

Financing stage: The Israel Innovation Authority has allocated a designated budget to support our development, underscoring both the novelty of our solution and the significant potential it holds for transforming patient care.